Clinical Trials Directory

Trials / Completed

CompletedNCT00520754

Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children

The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
15 (actual)
Sponsor
UCB Pharma · Industry
Sex
All
Age
2 Months – 24 Months
Healthy volunteers
Not accepted

Summary

Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children

Conditions

Interventions

TypeNameDescription
DRUGlevocetirizine dihydrochloride

Timeline

Start date
2001-12-01
Primary completion
2003-03-01
Completion
2003-03-01
First posted
2007-08-27
Last updated
2013-12-12

Source: ClinicalTrials.gov record NCT00520754. Inclusion in this directory is not an endorsement.